Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
The US Treasury is proposing the COINS Act to restrict high-tech investments in China, specifically targeting the biotech sector while exempting certain deals.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The US Treasury proposed rules to crack down on high-tech investments in China and other adversaries, leaving investors guessing about the impact on biotech deals. In response, China urged the US to halt the proposed expansion of outbound investment curbs and hit back at the tightened limits.
The coverage quieted without a definitive conclusion regarding the final outcome of the restrictions.
Epilogue added 21d ago, after coverage quieted.
The brief
According to coverage from the Toronto Star, this proposal represents a significant crackdown on how US capital flows into sensitive technological fields. A primary focus of these new restrictions is the biotech industry, which is now being swept into the scope of the proposed limits. However, the current framework appears to spare licensing deals between Big Pharma and Chinese entities, creating a nuanced distinction between direct investment and specific commercial agreements. Reporting from Reuters and Bloomberg emphasizes the immediate diplomatic friction caused by this proposal. Both outlets note that China has hit back at the US move, with Chinese officials urging the United States to halt the expansion of these outbound investment curbs.
The tension reflects a broader geopolitical struggle over technological dominance. Meanwhile, Endpoints News has raised questions regarding whether these regulatory shifts will effectively kill off biotech deals between the US and China, highlighting the precarious position of firms operating in the life sciences space who now face a more restrictive regulatory environment. Contextual analysis from Axios indicates that the rules associated with the Trump administration's approach to China biotech are leaving investors guessing. The lack of absolute clarity regarding which specific transactions are prohibited and which are permitted creates significant market uncertainty. This matters now because biotech relies heavily on cross-border collaboration and capital flows.
The distinction between general high-tech investment and Big Pharma's licensing deals suggests a strategic attempt to balance national security interests with the continued availability of pharmaceutical innovations, though the practical application of these rules remains unclear to market participants. Looking ahead, observers will be monitoring how the US Treasury clarifies the specific boundaries of the COINS Act to resolve the uncertainty cited by Axios. Future developments will likely center on whether the US maintains the exemptions for Big Pharma licensing or if those too are eventually brought under restriction. Additionally, the international community will watch for further official responses from China as it continues to urge the US to abandon these investment limits. The outcome of these proposed rules will determine the future viability of US-China biotech partnerships and the overall flow of venture capital into adversarial high-tech sectors.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (94% supported) Updated 22d ago.
Quick answers
What is the COINS Act proposal?
It is a US Treasury proposal to crack down on outbound investments in high-tech sectors within China and other adversaries.
Which sector is specifically targeted by the new rules?
The biotech sector is being swept into the proposed restrictions, though Big Pharma's China licensing deals are currently spared.
How has China responded to these proposals?
China has hit back at the proposal and urged the US to halt the expansion of these investment curbs.
Coverage (5)
- China urges US to halt proposed expansion of outbound investment curbs Reuters · 26d ago
- China Hits Back at US Proposal to Tighten Investment Limits Bloomberg · 26d ago
- Trump's China biotech rules leave investors guessing Axios · 26d ago
- US Treasury proposes a rule to crack down on high-tech investments in China, other adversaries Toronto Star · 26d ago
- Post-Hoc Live: Did the US just kill off China biotech deals? Endpoints News · 26d ago
Topics
Related trends
China Signals Its Intention to Land on Jupiter's Moon Callisto
China's Tianwen-4 mission signals an attempt to land on Jupiter's moon Callisto, marking a major step in deep-space exploration.
Taiwan may take a backseat when Xi and Trump meet for a third time at an APEC summit
Taiwan navigates a delicate diplomatic presence at the China-hosted APEC summit as Xi Jinping and Donald Trump prepare for their third meeting, with Taipei sending Acer founder Stan Shih as envoy.
EXCLUSIVE: Trump's China data center curb advances despite Amazon, Google, Meta lobbying
Trump administration advances China data center restrictions despite intense lobbying from Amazon, Google, Meta, and Microsoft over AI infrastructure impacts.
China and Canada expand tariff relief while Ottawa-Washington relations are strained
China and Canada expand tariff relief as Ottawa-Washington relations remain strained, according to coverage from AP News and the Prime Minister of Canada.
Trump arrives just as Southeast Asian summit is ending, but still looms over talks
President Trump arrived in Manila on November 17, 2026, to begin a three-day Asia trip that includes a Quad meeting, a trade statement with Thailand, and a planned visit to China for nuclear talks with Xi Jinping and Vladimir Putin.
Tracking China’s War of Words Against Japan
Recent reporting tracks an expanding campaign by China involving transnational repression and cognitive warfare targeting Japan.